GLP-1 Drug Makers Face Lawsuits Over Rare Vision Loss Claims

A wave of litigation has targeted manufacturers of GLP-1 drugs, with hundreds of consumers filing claims that these medications increased their risk of developing a rare type of vision loss. The lawsuits allege that the drugs caused anterior ischemic optic neuropathy (NAION), a condition characterized by a sudden drop in blood flow to the optic nerve, resulting in immediate sight impairment.

Details of the Legal Action

As reported by the Wall Street Journal, patients involved in the suits claim the medications were responsible for their diagnosis of NAION. This specific eye condition is identified by the American Academy of Ophthalmology and the National Eye Institute as the most common cause of acute optic nerve injury in adults over the age of fifty. These institutions describe the event as an "eye stroke."

Douglas Lazarow, an ophthalmologist at New York University Langone Health, emphasized the severity of the situation. He noted that there is currently no treatment available for NAION, which means the condition can lead to very severe vision loss.

Manufacturer Responses

The two companies named in the lawsuits, Novo Nordisk and Eli Lilly, have denied the allegations. Novo Nordisk, the maker of Ozempic and Wegovy, stated that the lawsuits are baseless. The company pointed to research funded by itself that found no increase in the risk of NAION associated with its drugs.

Eli Lilly, manufacturer of Mounjaro and Zepbound, confirmed it continues to monitor safety data. The company asserted that existing studies do not prove that GLP-1 medications cause this specific health issue.

Understanding NAION Risks

NAION typically causes sudden, painless vision loss in one eye. Symptoms may include blurred or dimmed vision, loss of peripheral sight, or reduced color perception. These signs often appear immediately upon waking in the morning.

Major risk factors for the condition include advancing age, diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, and smoking. Because many individuals taking GLP-1 drugs have diabetes or obesity, some underlying risk factors may contribute to vision problems independently of the medication.

Diabetes itself is an established risk factor for NAION, which complicates observational studies attempting to separate the effects of the disease from those of the drug. Vision loss resulting from NAION is frequently permanent. While some patients may recover partial sight over time, there is no proven treatment to reverse optic nerve damage.

Experts advise that patients should not discontinue prescribed GLP-1 medications without first consulting their healthcare provider. For many individuals with diabetes or obesity, the proven benefits of these drugs may outweigh potential risks to vision.